457 related articles for article (PubMed ID: 31426130)
21. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
22. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
[TBL] [Abstract][Full Text] [Related]
23. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
24. PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-κB pathway.
Yao N; Chen Q; Shi W; Tang L; Fu Y
Mol Carcinog; 2019 Jul; 58(7):1291-1302. PubMed ID: 30968979
[TBL] [Abstract][Full Text] [Related]
25. Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer.
Zhao M; Tominaga Y; Ohuchida K; Mizumoto K; Cui L; Kozono S; Fujita H; Maeyama R; Toma H; Tanaka M
Cancer Sci; 2012 Jan; 103(1):58-66. PubMed ID: 21954965
[TBL] [Abstract][Full Text] [Related]
26. Ginsenoside Rg3 suppresses the growth of gemcitabine-resistant pancreatic cancer cells by upregulating lncRNA-CASC2 and activating PTEN signaling.
Zou J; Su H; Zou C; Liang X; Fei Z
J Biochem Mol Toxicol; 2020 Jun; 34(6):e22480. PubMed ID: 32104955
[TBL] [Abstract][Full Text] [Related]
27. Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil.
Kurata N; Fujita H; Ohuchida K; Mizumoto K; Mahawithitwong P; Sakai H; Onimaru M; Manabe T; Ohtsuka T; Tanaka M
Int J Oncol; 2011 Aug; 39(2):473-82. PubMed ID: 21617862
[TBL] [Abstract][Full Text] [Related]
28. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma.
Palam LR; Gore J; Craven KE; Wilson JL; Korc M
Cell Death Dis; 2015 Oct; 6(10):e1913. PubMed ID: 26469962
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of
Phan T; Nguyen VH; Buettner R; Morales C; Yang L; Wong P; Tsai W; Salazar MD; Gil Z; Diamond DJ; Rabinowitz JD; Rosen S; Melstrom LG
Int J Biol Sci; 2021; 17(9):2240-2251. PubMed ID: 34239352
[TBL] [Abstract][Full Text] [Related]
30. Silencing of IGHG1 reverses the resistance of pancreatic cancer to multidrug chemotherapy by modulating autophagy.
Tian Y; Han W; Fu L; Lv K; Zhou X
Environ Toxicol; 2023 Aug; 38(8):1835-1845. PubMed ID: 37186415
[TBL] [Abstract][Full Text] [Related]
31. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Gulbinas A; Dambrauskas Z
World J Gastroenterol; 2015 Dec; 21(46):13004-19. PubMed ID: 26675757
[TBL] [Abstract][Full Text] [Related]
32. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
[TBL] [Abstract][Full Text] [Related]
33. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
Suzuki K; Aiura K; Matsuda S; Itano O; Takeuchi O; Umezawa K; Kitagawa Y
Clin Exp Metastasis; 2013 Apr; 30(4):381-92. PubMed ID: 23111540
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer.
Ma G; Sun Y; Fu S
Int J Clin Exp Pathol; 2015; 8(10):13284-8. PubMed ID: 26722531
[TBL] [Abstract][Full Text] [Related]
35. Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma.
Sun H; Ge Y; Liu J; Li Z; Li H; Zhao T; Wang X; Feng Y; Wang H; Gao S; Shi L; Yang S; Sun P; Chang A; Hao J; Huang C
Oncogene; 2024 Mar; 43(11):776-788. PubMed ID: 38243080
[TBL] [Abstract][Full Text] [Related]
36. Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition.
Jin H; Zhao Y; Zhang S; Yang J; Zhang X; Ma S
Mol Med Rep; 2018 May; 17(5):7274-7280. PubMed ID: 29568909
[TBL] [Abstract][Full Text] [Related]
37. Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer.
Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake M; Higuchi T; Oshiro H; Zhang Z; Razmjooei S; Wangsiricharoen S; Bouvet M; Singh SR; Unno M; Hoffman RM
Cancer Lett; 2018 Sep; 432():251-259. PubMed ID: 29928962
[TBL] [Abstract][Full Text] [Related]
38. MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells.
Lin Y; Ge X; Wen Y; Shi ZM; Chen QD; Wang M; Liu LZ; Jiang BH; Lu Y
Oncotarget; 2016 Oct; 7(43):70857-70868. PubMed ID: 27765914
[TBL] [Abstract][Full Text] [Related]
39. Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer.
Du X; Zhao YP; Zhang TP; Zhou L; Chen G; Wang TX; You L; Shu H
Arch Med Res; 2014 Jan; 45(1):15-20. PubMed ID: 24316112
[TBL] [Abstract][Full Text] [Related]
40. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
Wang F; Zhang Z
Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
